ATE399178T1 - Riproximin, ein neues typ ii ribosom- inaktivierendes protein und seine verwendung - Google Patents

Riproximin, ein neues typ ii ribosom- inaktivierendes protein und seine verwendung

Info

Publication number
ATE399178T1
ATE399178T1 AT06706681T AT06706681T ATE399178T1 AT E399178 T1 ATE399178 T1 AT E399178T1 AT 06706681 T AT06706681 T AT 06706681T AT 06706681 T AT06706681 T AT 06706681T AT E399178 T1 ATE399178 T1 AT E399178T1
Authority
AT
Austria
Prior art keywords
riproximin
new type
ribosome inactivation
protein
inactivation protein
Prior art date
Application number
AT06706681T
Other languages
English (en)
Inventor
Cristina Voss
Martin Berger
Carlos Schumacher
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of ATE399178T1 publication Critical patent/ATE399178T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
AT06706681T 2005-02-04 2006-02-06 Riproximin, ein neues typ ii ribosom- inaktivierendes protein und seine verwendung ATE399178T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05002356A EP1688429A1 (de) 2005-02-04 2005-02-04 Riproximin, ein neues Typ II Ribosom-inaktivierendes Protein und seine Verwendung

Publications (1)

Publication Number Publication Date
ATE399178T1 true ATE399178T1 (de) 2008-07-15

Family

ID=34933591

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06706681T ATE399178T1 (de) 2005-02-04 2006-02-06 Riproximin, ein neues typ ii ribosom- inaktivierendes protein und seine verwendung

Country Status (9)

Country Link
US (1) US20090137502A1 (de)
EP (2) EP1688429A1 (de)
JP (1) JP2008528045A (de)
AT (1) ATE399178T1 (de)
CA (1) CA2596514A1 (de)
DE (1) DE602006001579D1 (de)
ES (1) ES2309945T3 (de)
MX (1) MX2007008772A (de)
WO (1) WO2006082098A1 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0335476A3 (de) * 1984-02-08 1989-12-13 Cetus Corporation Rekombinante Verfahren für die Herstellung von Ricin-A, Ricin-B, Ricin oder Diphterietoxin-A oder AB'-Fragment, Wirte und Vektoren dafür und Konjugate, die Ricintoxin A-Kette oder Diphterietoxin enthalten
EP0196762A1 (de) * 1985-03-29 1986-10-08 Cetus Corporation Rekombinante Ricinfragmente, diese exprimierende Vektoren und transformierte Wirte, die Modifikation von DNS-Sequenzen und Isolierung von mRNS
DE19526206A1 (de) * 1995-07-18 1997-01-23 Asche Ag Mittel zur Behandlung von Infektionskrankheiten
US6803358B1 (en) * 2000-04-14 2004-10-12 Twinstrand Therapeutics Inc. Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
GB9909796D0 (en) * 1999-04-28 1999-06-23 Plant Bioscience Ltd Pesticidal fumes

Also Published As

Publication number Publication date
EP1846441A1 (de) 2007-10-24
EP1846441B1 (de) 2008-06-25
JP2008528045A (ja) 2008-07-31
US20090137502A1 (en) 2009-05-28
WO2006082098A8 (en) 2007-09-20
DE602006001579D1 (de) 2008-08-07
WO2006082098A1 (en) 2006-08-10
CA2596514A1 (en) 2006-08-10
MX2007008772A (es) 2008-03-10
EP1688429A1 (de) 2006-08-09
ES2309945T3 (es) 2008-12-16

Similar Documents

Publication Publication Date Title
HK1224329A1 (zh) 種新型的以蛋白為基礎的治療用分子
CY1116279T1 (el) Η χρηση των ανθρωπινων κυτταρων προελευσης μυελογενους λευχαιμιας για την εκφραση αντισωματων
BRPI0519766A2 (pt) proteases Ácidas féngicas
CY1111716T1 (el) Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων
DE112007001307A5 (de) Mikrobiologische Herstellung von 3-Hydroxyisobuttersäure
BRPI0514377A (pt) derivados tricìclicos fundidos para o tratamento de distúrbios psicóticos
EA200602038A1 (ru) Азинилимидазоазины и азинилкарбоксамиды
DE602005013819D1 (de) Pyridincarbonsäureamidderivate zur verwendung als antikrebsmittel
ATE512141T1 (de) Verwendung von tetrahydrobenzoxazinen als antioxidantien
DE602004024609D1 (de) Korrektur von Ausrichtungsfehlern
ATE557038T1 (de) Herstellung von rekombinantem il-18 bindendem protein
DE602006007048D1 (de) Viskositäts- und Zirkulationssteuerung von Fabstoff für den Druck von Linsengussformen
DE602005009255D1 (de) Amid-prodrug von gemcitabin, zusammensetzungen und verwendung damit
EA200801560A1 (ru) Бифенилкарбоксамиды
ATE524183T1 (de) Verwendung von sanglifehrin bei der hcv-therapie
DE602006004911D1 (de) Gasphasenoxidationskatalysator und dessen Verwendung zur Herstellung von Acrylsäure
ATE512970T1 (de) Dimere von artemisininderivaten, deren herstellung und deren therapeutische verwendung
DE602006006009D1 (de) Methode zur Herstellung von Acrylsäure
DE502006004941D1 (de) Von hohlprofilen
DE602006003108D1 (de) Methode zur Verbesserung der Ausbeute bei der Proteinreinigung mittels Gelfiltrationschromatographie und Arginin
DE502006008804D1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
DE502005003027D1 (de) Elektrolysezelle zur herstellung von alkalimetall
DE602005015297D1 (de) Verwendung von ozon zur verbesserung des knetvorgangs
ATE507222T1 (de) 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren
ATE515501T1 (de) Kristalline base von trans-1-((1r, 3s)-6-chlor-3- phenylindan-1-yl)-3,3-dimethylpiperazin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1846441

Country of ref document: EP

REN Ceased due to non-payment of the annual fee